百草枯20SL标准制剂摄入剂量、呕吐与结局的关系
该研究在斯里兰卡10家医院前瞻性纳入2003—2008年百草枯SL自服中毒患者441例,评估自报摄入剂量与血浆百草枯浓度、病死率及死亡时间的一致性,并分析30分钟内呕吐与结局的关系。结果显示自报剂量与log血浆百草枯浓度呈高度显著线性趋势(p<.001),与病死率和死亡时间吻合良好;68.5%患者在摄入30分钟内呕吐,但30分钟内呕吐者血浆浓度更高(p=.008)、校正Cox模型风险比2.01(95%CI 1.45-2.77)、病死率更高(81.7% vs 54.4%,p<.001)。最高摄入剂量组30分钟内呕吐比例仅82.1%。作者认为现行FAO催吐剂规格不能有效预防百草枯SL制剂摄入后死亡。
要点
- 441例百草枯SL自服中毒患者中,435例结局已知,322例(74.0%)在42天内死亡,死亡中位时间1.3(0.6-4.4)天。
- 自报摄入剂量中位数为15至<30 mL,与log血浆百草枯浓度呈高度显著线性趋势(p<.001),与病死率和死亡时间吻合良好。
- 300/438例(68.5%)在摄入30分钟内呕吐,但30分钟内呕吐者血浆百草枯浓度更高(p=.008),校正Cox模型风险比2.01(95%CI 1.45-2.77)。
- 30分钟内呕吐者病死率241/295(81.7%),未在30分钟内呕吐者68/125(54.4%),差异显著(p<.001)。
- 最高摄入剂量组30分钟内呕吐比例仅82.1%,91例到院前未呕吐者中43例(47.3%)死亡,作者认为现行FAO规格不能有效预防死亡。
适用人群与场景
- 2003—2008年在斯里兰卡10家医院前瞻性纳入的百草枯SL制剂自服中毒患者,就诊时中位摄入时间为3.0(1.5-8.1)小时。
研究设计与关键结果
- 研究类型为前瞻性病例系列,纳入441例百草枯SL自服中毒患者,来自斯里兰卡10家医院,2003—2008年。
- 435例结局已知,322例(74.0%)在42天内死亡,死亡中位时间1.3(0.6-4.4)天。
- 自报摄入剂量中位数为15至<30 mL;log血浆百草枯浓度与自报摄入剂量呈高度显著线性趋势(p<.001),校正摄入至采血时间对数后模型拟合进一步改善。
- 347/438例(79.2%)到院前已呕吐,其中300例(68.5%)在摄入30分钟内呕吐,另12例(2.7%)呕吐时间未知。
- 呕吐比例与自报摄入剂量强相关(p<.001);最高摄入剂量组30分钟内呕吐比例仅升至83.3%。
- 30分钟内呕吐者血浆百草枯浓度更高(p=.008),校正Cox回归模型风险比2.01(95%CI 1.45-2.77)。
- 30分钟内呕吐者病死率241/295(81.7%),未在30分钟内呕吐者68/125(54.4%),p<.001。
- 到院前未呕吐的91例患者中43例(47.3%)死亡,1例结局未知;最高摄入剂量组30分钟内呕吐比例仅达82.1%。
证据类型、等级与局限
- 证据类型:前瞻性病例系列(10家医院,2003—2008年)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为自报摄入剂量是摄入剂量的有效标志物,与血浆百草枯浓度、病死率和死亡时间吻合良好。
- 作者认为30分钟内呕吐与约两倍死亡风险相关,且与更大摄入量和更高血百草枯浓度相关。
- 作者认为现行FAO规格中的催吐剂不能有效预防百草枯SL制剂摄入后死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: FAO specifications for liquid paraquat dichloride SL formulations require the use of an emetic agent to stimulate vomiting within 30 min of ingestion. To date, there is no high-quality evidence of efficacy, despite use of the PP796 emetic since 1979. We first examined the validity of patients' self-reported dose of paraquat ingested by examining the relationship with blood paraquat concentration and time to death for patients ingesting the standard paraquat SL formulation in a Sri Lankan cohort. As a secondary outcome, we assessed whether ingestion resulted in vomiting within 30 min and whether vomiting was associated with good outcome.
METHODS: Patients presenting with paraquat SL self-poisoning were prospectively studied in ten Sri Lankan hospitals in 2003-08. Data on reported dose ingested, incidence and timing of vomiting after ingestion, treatment received, plasma paraquat concentration, and outcome were collected prospectively on presentation to hospital. Time between ingestion and blood sampling was incorporated by covariate adjustment.
RESULTS: 441 patients were recruited to the case series, presenting a median (IQR) of 3.0 (1.5-8.1] h post ingestion. Outcome was known for 435 patients of whom 322 (74.0%) died within 42 days, a median of 1.3 (0.6-4.4) days post ingestion. Median reported dose ingested was 15 to <30 mL. There was a highly significant linear trend between log plasma paraquat and reported dose ingested (p < .001); adjustment for the log of the time from ingestion to sampling further improved the model fit. Case fatality and median time to death also showed good agreement with estimated ingestion amount. 347/438 patients (79.2%) were stated to have vomited before reaching the study hospital with 300 (68.5%) vomiting within 30 min of ingestion; time to vomiting was unknown for a further 12 (2.7%). The proportion vomiting was strongly associated with reported dose ingested (p < .001); of note the proportion vomiting within 30 min only increased to 83.3% for the highest ingestion group. Patients vomiting within 30 min had higher plasma paraquat concentrations (p = .008), and higher hazard ratio in the adjusted Cox regression model of 2.01 (95% CI 1.45-2.77) compared to those who did not. Vomiting within 30 min was associated with a higher case fatality (241/295 [81.7%] vs 68/125 [54.4%], p < .001). Forty-three (47.3%) of the 91 patients who did not vomit before reaching hospital died (one had unknown outcome).
CONCLUSION: Importantly, we found good agreement between reported dose ingested and plasma paraquat concentration, case fatality, and time to death, suggesting that the reported dose is a valid marker for the dose ingested. Vomiting occurred within 30 min for 68.5% of patients, exceeding the characteristics for a purported effective emetic in the FAO specifications. However, vomiting within 30 min was associated with approximately double the risk of death compared to those who did not vomit, larger paraquat ingestions, and higher blood paraquat concentrations. In addition, death occurred in many patients who did not vomit, and the proportion vomiting within 30 min only reached 82.1% for the highest ingested dose group. Overall, we found no evidence of benefit resulting from incorporation of the emetic, suggesting that the current FAO specification is not effective at preventing deaths after ingestion of the paraquat SL formulation.
参考来源
- Deuster E, Tomenson JA, Mohamed F, et al. Dose ingested, vomiting, and outcome in patients ingesting a standard paraquat 20SL formulation. Clin Toxicol (Phila). 2022. PMID: 36541442. doi:10.1080/15563650.2022.2142601
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。